Exagen Inc. Stock Price, News & Analysis

Exagen (Nasdaq: XGN) announced acceptance of six abstracts for ACR Convergence 2025, held Oct 24–29, 2025 in Chicago. The program includes a plenary presentation on Oct 27 highlighting a urinary tenascin C panel that may predict kidney function loss in lupus nephritis and several posters on anti-RA33, anti-PAD4, T cell biomarkers, a kidney-specific four-protein index, and a multianalyte lupus risk score to improve AVISE CTD diagnostic precision.

Exagen will host an Innovation Theater on Oct 27, 2:30–3:15pm CDT and staff the booth #1228 for follow-up.

Exagen (Nasdaq: XGN) will release financial results for the quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. A conference call and webcast to review results will be held at 8:30 a.m. ET / 5:30 a.m. PT with John Aballi, President and CEO, and Jeff Black, CFO.

Conference call details: U.S. dial-in 201-389-0918; international dial-in 877-407-0890; webcast available at investors.exagen.com. A telephone replay is available through Tuesday, November 18, 2025 (U.S. replay 201-612-7415; international replay 877-660-6853; replay passcode 13756599). A recording of the webcast will be posted about one hour after the call at investors.exagen.com.

Exagen (NASDAQ:XGN), a provider of innovative autoimmune testing solutions, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats and one-on-one meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, and the Cantor Global Healthcare Conference 2025 on September 3, 2025, in New York City.

Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing solutions provider, reported strong Q2 2025 financial results with record revenue of $17.2 million, representing 14% growth year-over-year. The company achieved significant milestones including a 14% increase in AVISE CTD test volume compared to Q1 2025 and an expanded ASP of $428.

Key financial metrics include a gross margin of 60.4% and operating expenses of $13 million. The company strengthened its financial position through a $20.2 million public offering and ended Q2 with $30.2 million in cash. Management provided full-year 2025 revenue guidance of $65-70 million, expecting positive adjusted EBITDA at the high end in Q4.

Notable corporate updates include the appointments of Dr. Michael Mahler as CSO and Chas McKhann to the Board of Directors.

Exagen Inc. (NASDAQ: XGN), a provider of autoimmune testing solutions, has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of life sciences industry experience, having served as President and CEO of Silk Road Medical and Apollo Endosurgery, both successfully acquired by Boston Scientific.

McKhann's extensive background includes roles as Chief Commercial Officer at Torax Medical and Intersect ENT, along with significant experience in leading turnaround and transformational growth at medical technology companies. He holds degrees from Stanford University, including an M.B.A.

Exagen (NASDAQ: XGN), a leader in autoimmune testing, has scheduled its Q2 2025 financial results announcement for July 29, 2025, before market opening. The company will host a conference call at 8:30 AM ET featuring CEO John Aballi and CFO Jeff Black.

Investors can join via phone (201-389-0918 U.S. or +1-877-407-0890 international) or through the webcast link on Exagen's investor relations website. A replay will be available until August 12, 2025, accessible by phone using passcode 13753132 or through the company website.

Exagen (XGN) has appointed Dr. Michael Mahler as Chief Scientific Officer to enhance its autoimmune diagnostics leadership. Dr. Mahler, who earned his Ph.D. from the University of Heidelberg, brings over 20 years of experience in immunology and autoimmune research. His impressive background includes collaboration with autoimmune research pioneers at the Scripps Research Institute and previous role as Senior VP of Research Development at Werfen. With over 300 peer-reviewed publications and multiple patents, Dr. Mahler's expertise in autoantigen discovery and diagnostic innovation will drive Exagen's strategic initiatives in precision diagnostics for autoimmune diseases.

Exagen Inc. (XGN) has successfully completed its public offering, raising approximately $20.2 million in gross proceeds. The offering included the sale of 3,350,000 shares of common stock, plus an additional 502,500 shares due to the full exercise of the underwriter's option, all priced at $5.25 per share. The transaction closed on May 9, 2025, with Canaccord Genuity acting as the sole bookrunner. The offering was conducted under Exagen's shelf registration statement previously filed with the SEC.

Exagen Inc. (XGN) has announced the pricing of its public offering of 3,350,000 shares of common stock at $5.25 per share. The offering is expected to generate gross proceeds of $17.6 million before deducting underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 502,500 shares under the same terms.

The offering, scheduled to close on May 9, 2025, is being conducted through Canaccord Genuity as the sole bookrunner. The public offering is made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on November 29, 2023.